Boston Scientific Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSX research report →
About the company
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns.
- CEO
- Michael F. Mahoney
- IPO
- 1992
- Employees
- 53,000
- HQ
- Marlborough, MA, US
Price Chart
- Market Cap
- $67.09B
- P/E
- 18.81
- P/S
- 3.25
- P/B
- 2.59
- EV/EBITDA
- 13.54
- Div Yield
- 0.00%
- Gross Margin
- 70.41%
- Op Margin
- 20.12%
- Net Margin
- 17.24%
- ROE
- 14.82%
- ROIC
- 9.90%
- Revenue
- $20.07B · 19.87%
- Net Income
- $2.89B · 55.66%
- EPS
- $1.96 · 55.56%
- Op Income
- $3.97B
- FCF YoY
- 38.30%
- 52W High
- $109.50
- 52W Low
- $42.25
- 50D MA
- $51.60
- 200D MA
- $78.43
- Beta
- 0.58
- Avg Volume
- 20.61M
Get TickerSpark's AI analysis on BSX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Monson Jonathan | other | 2,087 |
| Jul 1, 26 | Monson Jonathan | other | 1,010 |
| Jul 1, 26 | Monson Jonathan | other | 2,087 |
| May 28, 26 | Mahoney Michael F | other | 386,755 |
| May 20, 26 | Pegus Cheryl | buy | 1,770 |
| May 20, 26 | LUDWIG EDWARD J | buy | 3,580 |
| May 20, 26 | Habiger David C | buy | 2,250 |
| May 19, 26 | Habiger David C | buy | 2,200 |
| May 7, 26 | Zane Ellen M | other | 3,800 |
| May 7, 26 | WICHMANN DAVID S | other | 3,800 |
Our BSX coverage
Recent articles, reports, and earnings notes.
Boston Scientific (BSX): Growth Reset, Still a Buy
Boston Scientific remains a high-quality medtech compounder despite a guidance cut and softer U.S. WATCHMAN trends. Strong Electrophysiology growth, solid cash flow, and a compressed valuation keep the stock attractive.
Boston Scientific’s selloff is what a real medtech reset looks like
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
Boston Scientific Corporation (BSX) falls on Watchman concerns
Boston Scientific Corporation (BSX) falls sharply after management flagged declining standalone Watchman procedures and near-term competitive pressure. Despite strong recent earnings, the market is repricing growth expectations, sending shares lower on heavy volume as investors reassess the stock’s premium valuation.
Want a deeper read on BSX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.